| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adc048c2a637cc5389e0118ca5b5f27a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate |
2017-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_597199de2beb861b7d7c81ab0e22750b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f8562dcced893c005fb498a2a12e284 |
| publicationDate |
2021-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-037330-B1 |
| titleOfInvention |
MEDICINAL PRODUCT OBTAINED BY COMBINING AGONIST FXR AND ARB |
| abstract |
The invention relates to a combined pharmaceutical agent containing as active ingredients a farnesoid X-receptor agonist (FXR agonist) or a pharmaceutically acceptable salt thereof and an angiotensin II receptor blocker (ARB) or a pharmaceutically acceptable salt thereof, in which the FXR agonist is obeticholic acid and ARB is losartan, candesartan, or valsartan. The invention also includes the use of this combination pharmaceutical agent for the preparation of an agent for inhibiting liver fibrosis in non-alcoholic steatohepatitis (NASH). The invention provides an effective treatment for NASH. |
| priorityDate |
2016-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |